title: Early accelerated approval for highly targeted cancer drugs.
authors.affiliation: Massachusetts General Hospital Cancer Center, Boston, USA.
authors.forename: Bruce A
authors.initials: BA
authors.lastname: Chabner
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D000077547:Crizotinib; D017277:Drug Approval / Q000379:methods; D015507:Drugs, Investigational / Q000627:therapeutic use; D006801:Humans; D007211:Indoles / Q000627:therapeutic use; D009369:Neoplasms / Q000188:drug therapy*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011720:Pyrazoles / Q000627:therapeutic use; D011725:Pyridines / Q000627:therapeutic use; D013449:Sulfonamides / Q000627:therapeutic use; D013997:Time Factors; D014481:United States; D014486:United States Food and Drug Administration; D000077484:Vemurafenib
chemical_list: D000970:Antineoplastic Agents; D015507:Drugs, Investigational; D007211:Indoles; D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D011725:Pyridines; D013449:Sulfonamides; D000077484:Vemurafenib; D000077547:Crizotinib